Antara (fenofibrate) and Alcohol / Food Interactions
There are 2 alcohol/food/lifestyle interactions with Antara (fenofibrate) which include:
Nicotine ↔ fenofibrate
Moderate Drug Interaction
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with fenofibrate may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of CYP450 2C19, 2A6, and 2C9 isoenzymes. The proposed mechanism, based on in vitro data, is decreased clearance due to fenofibrate-mediated inhibition of CYP450 2C19, 2A6, and 2C9.
MANAGEMENT: Until more information is available, caution is advised if fenofibrate is used concomitantly with drugs that are substrates of CYP450 2C19, 2A6, or 2C9 isoenzymes, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever fenofibrate is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Antara (fenofibrate)." Lupin Pharmaceuticals Inc, Baltimore, MD.
High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)
Major Potential Hazard, Moderate plausibility
fibric acid derivatives - HDL cholesterol
There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy. The decrease has been reported to occur within 2 weeks to years after initiation of therapy. It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn. Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.
Antara (fenofibrate) drug interactions
There are 129 drug interactions with Antara (fenofibrate)
Antara (fenofibrate) disease interactions
There are 7 disease interactions with Antara (fenofibrate) which include:
- biliary cirrhosis
- HDL cholesterol
- liver disease
- renal dysfunction
- hematological changes
More about Antara (fenofibrate)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 1 Review
- Drug class: fibric acid derivatives
- FDA Approval History
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.